5LU.F SIMRIS ALG AB B
- Market cap
- EUR 4.59M
- P/E
- -
- P/B
- 81.31x
- ROE
- -3,163.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5LU.F undervalued?
Graham numberThe Graham number of SIMRIS ALG AB B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SIMRIS ALG AB B fundamental analysis
No fundamental analysis for SIMRIS ALG AB B yet.
SIMRIS ALG AB B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SIMRIS ALG AB B
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammenhög, Sweden.
Full company profileSIMRIS ALG AB B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SIMRIS ALG AB B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 6.14M | 4.08M | 4.35M | 2.89M | 1.62M | 1.24M |
| Gross Profit | -2.07M | -742K | 2.01M | 1.22M | 1.77M | 520K |
| Operating Income | -28.9M | -24.7M | -36.6M | -34.7M | -29.6M | -22.1M |
| EBITDA | - | -18.0M | -22.4M | -17.6M | -14.5M | -8.22M |
| Net Income | -28.4M | -24.4M | -37.3M | -34.6M | -26.8M | -24.3M |
| EPS | -0.24 | -0.13 | -0.11 | -0.06 | -0.03 | -0.02 |
| Balance Sheet | ||||||
| Total Assets | 29.2M | 186M | 175M | 157M | 148M | 138M |
| Total Liabilities | 11.0M | 163M | 149M | 151M | 149M | 137M |
| Shareholders' Equity | 18.2M | 23.0M | 25.6M | 5.64M | -470K | 767K |
| Cash & Short-term Investments | 961K | 3.99M | 5.67M | 1.95M | 1.47M | 7.99M |
| Cash Flow | ||||||
| Operating Cash Flow | -18.1M | -18.2M | -36.4M | -18.0M | -16.0M | -13.0M |
| Capital Expenditure | 253K | 22.4M | 1.61M | 613K | 224K | 0.00 |
| Free Cash Flow | -18.4M | -40.6M | -38.0M | -18.6M | -16.3M | -13.0M |
| Ratios | ||||||
| ROE | -155.6% | -106.0% | -145.6% | -613.5% | - | -3,163.8% |
| ROA | -97.1% | -13.2% | -21.4% | -22.0% | -18.1% | -17.6% |
| Net Profit Margin | -462.0% | -598.6% | -856.8% | -1,197.4% | -1,660.1% | -1,956.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SIMRIS ALG AB B dividends
SIMRIS ALG AB B has not paid dividends in the last 5 fiscal years.
Who owns SIMRIS ALG AB B
- Insiders 3.53%
- Institutions 1.10%
- Public & others 95.37%
- Shares outstanding 1.35B
- Free float 1.26B
SIMRIS ALG AB B company profile
- Company name
- SIMRIS ALG AB B
- Ticker
- 5LU.F
- ISIN
- SE0008091664
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- HerrestadsvAegen 24A, Hammenhög, Sweden, 276 50
- Phone
- 46 4 14 44 50 50
- Website
- simrisgroup.com
About SIMRIS ALG AB B
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammenhög, Sweden.
SIMRIS ALG AB B management
1- Mr. Christoffer TellChief Financial Officer · born 1987